The Joint Clinical Assessment (JCA) faces the challenge of preparing evidence without clear guidelines from the HTA Coordination Group, leading to potential last-minute rushes for health technology developers (HTDs) to generate necessary data. To mitigate this risk, HTDs are increasingly using artificial intelligence (AI) to enhance the efficiency and quality of their PICO (Problem, Intervention, Comparison, Outcome) planning. While AI adeptly synthesizes information and finds relevant precedents, it cannot predict decision-relevant evidence; human expertise remains crucial for interpreting findings and aligning them with the evolving reimbursement landscape.
Clarivate’s JCA and HTA Centre of Excellence employs a multidisciplinary approach, combining AI tools with human judgment to improve PICO readiness and mitigate evidence gaps. Their methods involve integrating insights from clinicians and payers to ensure that assumptions are relevant and grounded in real-world practice. This collaborative approach aims to enhance the quality of submissions and streamline the preparation process for HTDs in navigating the complexities of JCA.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://clarivate.com/life-sciences-healthcare/blog/the-promise-and-limitations-of-ai-in-jca-pico-planning-for-pharmas-and-medtechs/
